Xeris Biopharma Holdings, Inc.
NASDAQXERS has had a standout week — up 16.6% to $8.73 — yet the stock sits well below where its most bullish analyst believes it belongs, and options traders are quietly turning more cautious even as the rally runs. The clearest acceleration in sentiment came from the analyst community. Leerink Partners raised its price target from $12 to $16 on September 10, maintaining an Outperform…
Snapshot as of 23 Sept 2026
XERS has had a standout week — up 16.6% to $8.73 — yet the stock sits well below where its most bullish analyst believes it belongs, and options traders are quietly turning more cautious even as the rally runs. The…
Short interest updated daily, real-time options flow, analyst consensus deltas, 13F positioning, ORTEX Alpha signals, and every article ORTEX publishes for XERS — free to start on ORTEX.
Sign up for free →Open XERS on ORTEX